Conference
Rates of trastuzumab-associated cardiotoxicity in patients with HER2-positive breast cancer at a tertiary cancer centre.
Abstract
e12030
Background: Human epidermal growth factor receptor 2 ( HER2) is overexpressed in 15-25% of breast cancers and associated with decreased rates of survival. Trastuzumab (TZ) is a humanized monoclonal antibody that binds against HER-2 and improves both disease free and overall survival in the adjuvant setting. A side effect of TZ is reversible cardiotoxicity(CT), which can lead to early termination of TZ. The rates of TZ …
Authors
Kumar Tyagi N; Arora R; Partridge A; Tharmabala M; Mukherjee S; Leong D; Dhesy-Thind SK
Volume
35
Pagination
pp. e12030-e12030
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2017
DOI
10.1200/jco.2017.35.15_suppl.e12030
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X